Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A13 | Q16696 | 5/20 | 0.47 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14938599 | 0.85 | HRH3 (0.38) | HRH3ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL7674618 | 0.75 | HRH3 (0.37) | CXCR4HRH3LMNAL3MBTL1 | |
| SCHEMBL14938678 | 0.73 | CYP2A13 (0.57) | CYP2A13CXCR4HRH3ALDH1A1CYP2C9 | |
| SCHEMBL15415321 | 0.72 | ALDH1A1 (0.40) | ALDH1A1CYP2C9ALOX15HSD17B10MEN1 | |
| SCHEMBL1481687 | 0.71 | CXCR4 (0.49) | CYP2A13CXCR4HRH3ALDH1A1CYP2C9 | |
| SCHEMBL15416054 | 0.69 | CXCR4 (0.54) | CYP2A13CXCR4HRH3ALDH1A1CYP2C9 | |
| SCHEMBL17331349 | 0.69 | SMN1; SMN2 (0.41) | CYP2A13CXCR4HRH3ALDH1A1CYP2C9 | |
| SCHEMBL1481690 | 0.68 | HRH3 (0.51) | CYP2A13CXCR4HRH3ALDH1A1CYP2C9 | |
| SCHEMBL8605946 | 0.68 | ALDH1A1 (0.49) | CYP2A13ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL949897 | 0.67 | SIGMAR1 (0.49) | CYP2A13CXCR4ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE48622-E1 | Therapeutically active pyrazolo-pyrimidine derivatives | UCB Biopharma SRL (BE) | 2021-07-06 | — | — | US | disclosed |
| EP-3157922-B1 | PYRAZOLO-PYRIDINE DERIVATIVES AS KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2018-11-28 | — | — | EP | disclosed |
| US-10087180-B2 | Pyrazolo-pyridine derivatives as kinase inhibitors | UCB BIOPHARMA SPRL (BE) | 2018-10-02 | — | — | US | disclosed |
| US-20180201622-A1 | Fused Bicyclic Heteroaromatic Derivatives as Kinase Inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2018-07-19 | — | — | US | disclosed |
| US-10000497-B2 | Fused bicyclic heteroaromatic derivatives as kinase inhibitors | UCB BIOPHARMA SPRL (BY) | 2018-06-19 | — | — | US | disclosed |
| US-9969748-B2 | Fused bicyclic heteroaromatic derivatives as kinase inhibitors | UCB BIOPHARMA SPRL (BE) | 2018-05-15 | — | — | US | disclosed |
| EP-2935269-B1 | THERAPEUTICALLY ACTIVE PYRAZOLO-PYRIMIDINE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2018-04-11 | — | — | EP | disclosed |
| US-9714248-B2 | Therapeutically active pyrazolo-pyrimidine derivatives | UCB PHARMA SA (BE) | 2017-07-25 | — | — | US | disclosed |
| US-20170129905-A1 | Fused Bicyclic Heteroaromatic Derivatives as Kinase Inhibitors | UCB BIOPHARMA SPRL (BE) | 2017-05-11 | — | — | US | disclosed |
| US-20170121324-A1 | Pyrazolo-Pyridine Derivatives as Kinase Inhibitors | UCB BIOPHARMA SPRL (BE) | 2017-05-04 | — | — | US | disclosed |
| US-20160194329-A1 | Therapeutically Active Pyrazolo-Pyrimidine Derivatives | UCB PHARMA SA (BE) | 2016-07-07 | — | — | US | disclosed |
| WO-2015193168-A1 | FUSED BICYCLIC HETEROAROMATIC DERIVATIVES AS KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2015-12-23 | — | — | WO | disclosed |
| WO-2015193169-A1 | FUSED BICYCLIC HETEROAROMATIC DERIVATIVES AS KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2015-12-23 | — | — | WO | disclosed |
| WO-2015193167-A1 | PYRAZOLO-PYRIDINE DERIVATIVES AS KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2015-12-23 | — | — | WO | disclosed |
| EP-2935269-A1 | THERAPEUTICALLY ACTIVE PYRAZOLO-PYRIMIDINE DERIVATIVES | UCB Biopharma SPRL (BE) | 2015-10-28 | — | — | EP | disclosed |
| US-9096614-B2 | Therapeutically active thiazolo-pyrimidine derivatives | UCB PHARMA SA (BE) | 2015-08-04 | — | — | US | disclosed |
| US-20140315885-A1 | Therapeutically Active Thiazolo-Pyrimidine Derivatives | UCB PHARMA SA (BE) | 2014-10-23 | — | — | US | disclosed |
| EP-2776445-A1 | THERAPEUTICALLY ACTIVE THIAZOLO-PYRIMIDINE DERIVATIVES | UCB Pharma, S.A. (BE) | 2014-09-17 | — | — | EP | disclosed |
| WO-2014096423-A1 | THERAPEUTICALLY ACTIVE PYRAZOLO-PYRIMIDINE DERIVATIVES | UCB PHARMA S.A. (BE) | 2014-06-26 | — | — | WO | disclosed |
| WO-2013068458-A1 | THERAPEUTICALLY ACTIVE THIAZOLO-PYRIMIDINE DERIVATIVES | UCB PHARMA S.A. (BE) | 2013-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180201622-A1 | Fused Bicyclic Heteroaromatic Derivatives as Kinase Inhibitors | PI4KB, PI4KA, PI4K2B | CYP2A13 1386/4885CXCR4 2090/4885HRH3 1916/4885 |
| US-20160194329-A1 | Therapeutically Active Pyrazolo-Pyrimidine Derivatives | HAVCR2, TPMT, NFATC1 | CYP2A13 1634/4885CXCR4 460/4885HRH3 2098/4885 |
| US-20140315885-A1 | Therapeutically Active Thiazolo-Pyrimidine Derivatives | TPMT, IFNG, IRF3 | CYP2A13 1853/4885CXCR4 1522/4885HRH3 3779/4885 |
| US-10087180-B2 | Pyrazolo-pyridine derivatives as kinase inhibitors | PI4KA, PI4KB, PI4K2A | CYP2A13 2269/4885CXCR4 1244/4885HRH3 2486/4885 |
| US-20170129905-A1 | Fused Bicyclic Heteroaromatic Derivatives as Kinase Inhibitors | PI4KB, PI4KA, PI4K2B | CYP2A13 1386/4885CXCR4 2090/4885HRH3 1916/4885 |
| US-10000497-B2 | Fused bicyclic heteroaromatic derivatives as kinase inhibitors | PI4KB, PI4KA, PI4K2B | CYP2A13 1356/4885CXCR4 1815/4885HRH3 1669/4885 |
| US-20170121324-A1 | Pyrazolo-Pyridine Derivatives as Kinase Inhibitors | PI4KA, PI4KB, PI4K2A | CYP2A13 2269/4885CXCR4 1244/4885HRH3 2486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.